Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is a biotechnology company dedicated to developing breakthrough therapies for neurodegenerative diseases through our deep commitment to degeneration biology and principles of translational medicine. Denali is founded on the collaboration of leading scientists, industry experts, and investors who share the vision that scientific discovery energetically applied to translational medicine is the key to delivering effective therapies to patients.
We invite you to consider an opportunity with Denali to help achieve our goal of delivering meaningful therapeutics to patients.
Key Accountabilities/Core Job Responsibilities:
Lead internal large molecule CMC-focused mass spectrometry and extended characterization activities including primary sequence determination, PTM analysis, and higher order structure characterization for large molecule CMC portfolio.
Develop phase-appropriate product extended characterization strategies for large molecule CMC portfolio including elucidation of structure for early vs. late phase programs as well as characterization strategy for product variants and forced degraded samples.
Hands-on, technical execution of LC-MS based characterization activities to support comparability evaluations, inform CQA assessments, determine structure-function-activity relationships, and further product understanding.
Author and review technical development documents and relevant sections of health authority filings.
Maintain timely and accurate lab records consistent with good documentation practices.
Ensure rapid and timely analytical support for cell-line, bioprocess, and formulation development activities.
Support late phase analytical development and product characterization activities for one or more large molecule programs in CMC development.
Contribute to the development & implementation of overall analytical control strategy to enable commercialization of complex biotherapeutics.
Oversee product characterization strategy and execution including elucidation of structure as well as characterization of forced degraded panel and minor variants.
Perform critical quality attributes (CQAs) assessments to support phase-appropriate control system strategy.
Provide oversight of analytical method transfer, qualification, and validation activities at external/internal QC laboratories.
Provide oversight of analytical activities supporting late-phase process characterization and process validation studies at external/internal QC laboratories.
Qualifications/Skills:
Typically requires a PhD in Analytical Chemistry, Chemical Engineering, Biophysics or related scientific discipline and 3+ years of direct CMC-focused analytical development experience in protein therapeutics within the biotech/biopharma industry (MS with 8+ or BS with 10+ years' experience).
In depth knowledge and extensive hands-on experience developing and applying mass spectrometry-based methods (Intact/reduced MS, subunit analysis, peptide mapping, N-/O-glycosylation profiling, disulfide linkage determination, LC-MS/MS analysis) for protein sequence confirmation, identification and characterization of product variants, and comparability in the context of protein therapeutics.
Well versed in characterizing protein therapeutic product variants and forced degradation samples.
Previous experience authoring relevant IND/BLA sections (e.g. Analytical comparability, Elucidation of Structure, Justification of Specifications, etc.)
Previous experience in developing a wide array of analytical protein characterization and biophysical methods (e.g. HPLC-based methods, cIEF, capillary electrophoresis, LC/MS – based multi-attribute methods (MAM), peptide mapping, spectrophotometry, light scattering, etc.)
Demonstrated track record of successfully transferring and qualifying analytical methods for protein therapeutic development programs, developing control strategies, and successful health authority submissions
Strong grasp of statistical approaches for design-of-experiments (DoE) analytical method development, robustness testing, and data analysis.
Excellent communication, collaboration, organizational, and scientific problem-solving skills.
This compensation and benefits information is based on Denali’s good faith estimate as of the date of publication and may be modified in the future.
Denali is committed to its core company value of unity by creating a diverse and inclusive environment. We are proud to be an equal opportunity employer and do not discriminate against any employee or applicant for employment because of race, color, sex, age, national origin, religion, sexual orientation, gender identity and/or expression, status as a veteran, basis of disability, or any other federal, state, or local protected class.
Skills Required
- PhD in Analytical Chemistry, Chemical Engineering, Biophysics or related field (or MS with 8+ years, BS with 10+ years) with direct CMC-focused analytical development experience
- 3+ years direct CMC-focused analytical development experience in protein therapeutics (per PhD requirement) or equivalent per degree level
- In-depth knowledge and extensive hands-on experience developing and applying mass spectrometry-based methods (intact/reduced MS, subunit analysis, peptide mapping, LC-MS/MS) for protein therapeutics
- Experience with N-/O-glycosylation profiling, disulfide linkage determination, and characterization of product variants and forced degradation samples
- Experience authoring IND/BLA sections (e.g., Analytical Comparability, Elucidation of Structure, Justification of Specifications)
- Experience developing a broad panel of analytical and biophysical methods (HPLC-based methods, cIEF, capillary electrophoresis, MAM, peptide mapping, spectrophotometry, light scattering)
- Demonstrated experience transferring and qualifying analytical methods, developing control strategies, and supporting regulatory submissions
- Strong grasp of statistical approaches for DoE, robustness testing, and data analysis
- Excellent communication, collaboration, organizational, and scientific problem-solving skills
Denali Therapeutics Compensation & Benefits Highlights
The following summarizes recurring compensation and benefits themes identified from responses generated by popular LLMs to common candidate questions about Denali Therapeutics and has not been reviewed or approved by Denali Therapeutics.
-
Healthcare Strength — Health coverage is described as strong, with the employee premium covered in certain cases. Core medical benefits are consistently highlighted in public materials and postings.
-
Retirement Support — A 401(k) plan with employer safe-harbor contributions is confirmed by company materials. Contributions are described as being deposited each payroll, signaling dependable support for retirement savings.
-
Equity Value & Accessibility — An employee stock purchase plan is offered and enhanced by a “Cashless Participation” feature through a vendor partnership, improving ease of participation. Equity programs are also referenced in job postings and filings.
Denali Therapeutics Insights
What We Do
Denali Therapeutics is dedicated to defeating neurodegenerative diseases by breaking through historical barriers in scientific research and clinical development in order to deliver safe and effective medicines to patients and families. Our scientific approach is based on three core principles: rigorous assessment of genetic targets, engineering brain delivery, and using biomarkers to guide development. Our team thrives in a work environment that is scientifically driven, impact-focused, supportive, and collaborative. Our ability to have a positive impact on people’s lives is directly related to the trust we have in each other and our ability to unify our diverse backgrounds and experience behind our purpose to defeat degeneration.
.png)







